The agreement gives Chiesi exclusive rights for the development and commercialisation of ABO-101 to treat PH1.

AstraZeneca has signed a $555 million deal with a San Francisco-based biotech business Algen Biotechnologies, The Financial Times reported on Monday. The agreement with Algen gives AstraZeneca ...

A gene-editing tool that can turn genes on and off like a light switch has been developed. Turning a gene on means activating the production of ...

The inaugural Genetic Agency Technology Conference (GATC) on November 11th, 2025 will convene technical thought leaders, gene therapy developers, patients, their families, and patient advocates across ...

Metagenomi announces successful integration of large genes in human cells using a novel, compact CAST system for potential therapeutic applications. Metagenomi, Inc., a precision genetic medicines ...

Our RNAi play came from the understanding that personalization and the development of curated therapies are the future of ...

Founded in 2020 by Chilean biochemist Bernardo Pollak, Meristem is using precise gene editing techniques to develop local ...

Turning genes on and off is like flipping a light switch, controlling whether genes in a cell are active. When a gene is ...

While some scientists argue that agricultural gene editing regulations are overly restrictive, a new paper from the University of Adelaide emphasises the importance of clear regulations to ensure new ...

Genetic modification is back on the political agenda in New Zealand. The issue may not be as hotly contentious as it once was ...

Matthew Cobb is professor emeritus at the University of Manchester, UK, and author of The Genetic Age (Profile Books, 2022). On 24 February 1975, some 150 people met at the Asilomar Conference Grounds ...